Acquisition leverage Algorics was acquired by Precision for Medicine in March 2024, presenting an opportunity to cross-sell integrated biomarker-driven clinical research capabilities and leverage Precision’s global footprint to scaleAlgorics’ data services and resourcing offerings.

Global reach Precision for Medicine operates in 40 locations across North America, Europe and Asia-Pacific with 3,500 employees, enabling coordinated multi-region biomarker programs. Target prospects seeking global trial execution can benefit from this expanded scale.

Biomarker focus The combined organization emphasizes biomarker-driven clinical research and development, offering chances to upsell comprehensive biomarker strategy, assay development, data intelligence, and integrated trial design across existing client pipelines.

APAC expansion Recent openings in Japan and Singapore strengthen Asia-Pacific presence, creating opportunities to pursue Asia-based trials, local regulatory alignment, and access to regional biopharma partners seeking biomarker-enabled studies.

Leadership momentum Key senior hires in biospecimen solutions, labs translational sciences and oncology clinical development signal ongoing investment in core capabilities; leverage these moves to approach decision-makers with expanded service maps and proven leadership depth.